These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 19227153)
61. The difficult decision when to discontinue multidrug therapy in leprosy. Kato L Acta Leprol; 1987; 5(4):279-82. PubMed ID: 3327350 [No Abstract] [Full Text] [Related]
62. Mycobacterium leprae--millennium resistant! Leprosy control on the threshold of a new era. Visschedijk J; van de Broek J; Eggens H; Lever P; van Beers S; Klatser P Trop Med Int Health; 2000 Jun; 5(6):388-99. PubMed ID: 10929137 [TBL] [Abstract][Full Text] [Related]
63. Leprosy elimination in India--so near. Rao CK Indian J Lepr; 2005; 77(3):207-11. PubMed ID: 16353518 [No Abstract] [Full Text] [Related]
64. With scores still infected, India declares leprosy 'eliminated'. Padma TV Nat Med; 2006 Apr; 12(4):372. PubMed ID: 16598268 [No Abstract] [Full Text] [Related]
65. Drug-resistant leprosy: monitoring and current status. Williams DL; Gillis TP Lepr Rev; 2012 Sep; 83(3):269-81. PubMed ID: 23356028 [No Abstract] [Full Text] [Related]
66. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser; 1988; 768():1-51. PubMed ID: 3140498 [No Abstract] [Full Text] [Related]
67. Leprosy: a glossary. Virmond M; Grzybowski A; Virmond L Clin Dermatol; 2015; 33(1):8-18. PubMed ID: 25432806 [TBL] [Abstract][Full Text] [Related]
68. Eliminating leprosy as a public health problem--is the optimism justified? Noordeen SK; Roxas MG; Fine PE; Smith WC; Feenstra P; Gokhale SD; Joo LK; Huan-Ying L; Khalafalla G; Becx-Bleumink M; Srinivasan H; Rao CK; Lechat MF; Sansarricq H World Health Forum; 1996; 17(2):109-44. PubMed ID: 8936264 [TBL] [Abstract][Full Text] [Related]
69. Acceptance of WHO/MDT over the last 20 years. Lechat MF Int J Lepr Other Mycobact Dis; 2001 Sep; 69(3):241-6. PubMed ID: 11875769 [No Abstract] [Full Text] [Related]
71. Leprosy: steps along the journey of eradication. Bennett BH; Parker DL; Robson M Public Health Rep; 2008; 123(2):198-205. PubMed ID: 18457072 [No Abstract] [Full Text] [Related]
72. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues. Dhople AM; Namba K Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987 [TBL] [Abstract][Full Text] [Related]
73. [Present leprosy situation in the world in 2006]. Ishii N; Nagaoka Y; Mori S; Suzuki K Nihon Hansenbyo Gakkai Zasshi; 2007 Feb; 76(1):19-28. PubMed ID: 17315748 [TBL] [Abstract][Full Text] [Related]
74. Leprosy program in India at the crossroads. Rao PN Int J Lepr Other Mycobact Dis; 2005 Sep; 73(3):211-5. PubMed ID: 16830645 [No Abstract] [Full Text] [Related]
75. International Leprosy Congress 2002--lessons learned. Smith WC Lepr Rev; 2003 Mar; 74(1):7-10. PubMed ID: 12669927 [No Abstract] [Full Text] [Related]
76. Elimination of leprosy as a public health problem. Ebrahim GJ J Trop Pediatr; 1997 Dec; 43(6):316-7. PubMed ID: 9476450 [No Abstract] [Full Text] [Related]
77. Drug resistance in leprosy: An update following 70years of chemotherapy. Aubry A; Sammarco Rosa P; Chauffour A; Fletcher ML; Cambau E; Avanzi C Infect Dis Now; 2022 Aug; 52(5):243-251. PubMed ID: 35483633 [TBL] [Abstract][Full Text] [Related]
78. Progress and impact of multidrug therapy (MDT) implementation to leprosy control in Thailand. Ramasoota P; Intaratitaya T Nihon Rai Gakkai Zasshi; 1995 Nov; 64(3):214-9. PubMed ID: 8582880 [TBL] [Abstract][Full Text] [Related]